Every phacoemulsification procedure uses them. Every cataract outcome depends on how well they are selected, applied, and removed. Yet ophthalmic viscoelastic devices — OVDs — rarely receive the clinical depth they deserve. This is the guide that changes that.

What Is an Ophthalmic Viscoelastic Device?

An ophthalmic viscoelastic device (OVD) is a sterile, clear, biocompatible gel injected into the anterior chamber of the eye to facilitate intraocular surgery. The term "viscoelastic" precisely captures its dual physical character: it behaves as a viscous fluid under slow, sustained deformation (holding spaces open and protecting tissues) while simultaneously exhibiting elastic properties that allow it to absorb sudden mechanical energy — such as ultrasound transients during phacoemulsification — rather than transmitting them directly to delicate endothelial cells.

OVDs were introduced to ophthalmic surgery in 1972 by Miller and Stegmann, who used sodium hyaluronate derived from rooster comb tissue. Over the subsequent five decades, the class has expanded significantly — from a single formulation to a rich ecosystem of cohesive, dispersive, and combination products that are now integral to the modern phacoemulsification workflow.

The Six Critical Functions of an OVD

Understanding why OVDs matter begins with understanding what they must simultaneously accomplish under the demanding conditions of a live surgical field. An appropriately selected OVD fulfils six distinct roles — each as important as the others.

OVD Classification: Cohesive vs Dispersive

The most clinically consequential distinction in OVD science separates cohesive from dispersive agents. This classification, based entirely on rheological behaviour, governs how an OVD interacts with ocular tissues, how it responds to phaco irrigation, and how effectively it can be removed at the end of the case.

Cohesive OVDs

Cohesive OVDs are characterised by high molecular weight, high viscosity at low shear rates, and a strong tendency to remain as a single coherent gel mass. Their defining clinical advantage: they exit the eye as one bolus during I/A — rapidly, cleanly, and completely. This makes them easy to remove and minimises post-operative IOP spikes from residual OVD.

• Primary polymer: Sodium hyaluronate (HA), 1.0%–3.0% concentration
• Best for: Anterior chamber maintenance, capsular bag inflation, IOL delivery
• Removal profile: Rapid and complete — exits as a single unit with minimal I/A effort
• Limitation: Washes out from the endothelial surface under high-flow phaco irrigation; provides less sustained endothelial protection in prolonged or difficult cases
• Agaaz product: PURE-HYAL — Sodium Hyaluronate 1.4% PFS

Dispersive OVDs

Dispersive OVDs have lower molecular weight and viscosity, but under shear stress they fragment into small clusters that adhere to and coat tissue surfaces. This dispersive behaviour is precisely what makes them exceptional at protecting the corneal endothelium — even under the turbulent conditions of ultrasound energy — because the OVD fragments reform a protective coat even as phaco irrigation attempts to wash them away.

• Primary polymer: Hydroxypropyl methylcellulose (HPMC), typically 2.0%–2.5%
• Best for: Endothelial coating and protection throughout the phaco phase
• Removal profile: More challenging — fragments must be actively aspirated; bimanual I/A behind the IOL is essential
• Limitation: Poor space maintenance; inadequate for capsular bag inflation on its own; higher residual OVD risk
• Agaaz products: OP-VISC (HPMC 2%) · PURE-VISC (high-viscosity HPMC)

Agaaz Ophthalmics · Cohesive OVD

PURE-HYAL

Sodium Hyaluronate 1.4% · Pre-Filled Syringe · Cohesive · Pseudoplastic · Export-ready

1.4% Na Hyaluronate Pre-Filled Syringe High MW Cohesive CE-class compatible Cold-chain stable

View Full Specifications

The Rheology of Viscoelastics — Explained for Surgeons

Rheology — the science of how materials flow and deform — is what makes OVDs work. A practical understanding of three rheological phenomena will transform how you think about every OVD decision you make in theatre.

Pseudoplasticity (Shear-Thinning)

The most surgically critical property: viscosity decreases as the rate of mechanical shear increases. OVDs are thick and space-filling at rest — but when expressed through a narrow 26G or 27G cannula (high shear), their viscosity drops dramatically, allowing smooth injection. The moment shear stops, viscosity is restored. This is not a defect — it is precisely what allows a 10-million-mPa·s gel to pass through a sub-millimetre cannula without requiring excessive force.

Elasticity and Mechanical Damping

Beyond viscosity, OVDs possess true elastic properties — they store mechanical energy rather than simply dissipating it as heat. When phacoemulsification tip vibrations generate pressure transients in the anterior chamber, the elastic component of HA absorbs and distributes that energy across the gel matrix before it reaches endothelial cells. A purely viscous fluid would transmit those spikes directly. This is why HA is irreplaceable in complex, high-phaco-energy cases — its elasticity is a protective mechanism, not just a physical property.

Cohesivity Index (RetaH)

Quantified by the Cohesivity Index (RetaH), this metric describes the balance between cohesive forces within the gel and adhesive forces between the gel and surrounding tissues. Values approaching 1.0 indicate highly cohesive behaviour (exits as one unit); values approaching 0 indicate dispersive behaviour (fragments and adheres to surfaces). Most clinical OVD decisions are implicitly decisions about where on this continuum the selected product sits.

OVD Use at Each Stage of Phacoemulsification

OVDs are not a one-time intervention. They are actively managed throughout the case — injected, partially washed out, potentially replenished, and meticulously removed at the end. Understanding what is required at each stage prevents intraoperative problems and post-operative complications.

1. 01
   Pre-Capsulorhexis Chamber Fill

   A cohesive OVD (PURE-HYAL) is injected through the paracentesis to fill the anterior chamber, deepen the fornices, and flatten the anterior capsule. This creates controlled working space, counters zonular tension on the capsule, and allows a clean, controlled CCC initiation. This is also the stage where trypan blue staining with OP-BLUE is applied for low-view cases — injected after initial OVD to selectively stain the anterior capsule for visualisation.

2. 02
   Phacoemulsification Phase

   Cohesive OVD washes out rapidly during irrigation. Dispersive OVD (OP-VISC) adheres to the endothelial surface and persists through much of the phaco phase. In high-energy cases, complex nuclear densities, or compromised corneas, active dispersive OVD refill between nuclear quadrant removal is recommended — injecting fresh HPMC beneath the remaining lens material to restore the endothelial coat before proceeding.

3. 03
   Capsular Bag Inflation — Pre-IOL Insertion

   Following cortex removal, a fresh injection of cohesive OVD expands the capsular bag to its working diameter. Insufficient inflation at this stage is a leading cause of IOL misalignment, haptic entanglement, and zonular stress — particularly significant when implanting premium lenses like X-VIZ EDOF or OP-FOLD ASwhere positional precision directly affects refractive outcomes.

4. 04
   IOL Insertion and Positioning

   The viscoelastic lubricates the IOL-tissue interface and cushions the posterior capsule during lens unfolding. Hydrophilic lenses (OP-FOLD AS) unfold quickly; hydrophobic lenses (OP-VIEW AS) more slowly, giving more positioning time. In both cases, the capsular bag must remain inflated and stable throughout. Premium optic lenses require perfect centration that depends on optimal OVD management — see our full comparison of hydrophobic vs hydrophilic IOLs.

5. 05
   OVD Removal — The Most Underestimated Step

   Complete OVD removal is the most consistently undertreated step in phacoemulsification. Residual OVD — particularly dispersive HPMC fragments — obstructs the trabecular meshwork, causing transient IOP spikes of 10–40 mmHg in the first 4–24 hours post-operatively. Use bimanual I/A with a 180° rotation technique, actively aspirating behind the IOL optic and in the capsular bag fornices. In patients with pre-existing optic nerve vulnerability — see glaucoma context — prophylactic IOP-lowering medication is not optional.

The Soft-Shell Technique — The Gold Standard for High-Risk Cases

Introduced by Dr. Steve Arshinoff in 1999 and published in the Journal of Cataract and Refractive Surgery, the soft-shell technique is the most extensively validated strategy for simultaneously leveraging the advantages of both OVD types. It has become the standard of care in many high-volume centres globally for any case with endothelial vulnerability.

Clinical Indications for the Soft-Shell Technique

• Compromised corneal endothelium: Fuchs' endothelial dystrophy, low cell count (<1,500 cells/mm²)
• Dense, hard nuclear cataracts (grade 4–5, brown or black nucleus) requiring prolonged phaco time and energy
• Pseudoexfoliation syndrome with zonular weakness — where additional chamber stability is required
• Prior anterior segment surgery with adhesions or synechia
• Paediatric cataracts with highly elastic, resistant anterior capsules
• Any case where the surgeon anticipates extended phaco time or reduced surgical margin

Sodium Hyaluronate — The Molecular Science

Sodium hyaluronate (HA) is a naturally occurring, non-sulphated glycosaminoglycan consisting of alternating D-glucuronic acid and N-acetyl-D-glucosamine disaccharide units. It is found natively in the vitreous humour, aqueous humour, synovial fluid, and corneal stroma. This biological familiarity is one reason HA-based OVDs remain the gold standard for cohesive viscoelastics five decades after their introduction.

Molecular Weight and Viscosity

Commercial ophthalmic HA ranges from 1–4 million Daltons molecular weight. Higher MW = higher viscosity at zero shear and stronger pseudoplastic behaviour. Agaaz's PURE-HYAL at 1.4% occupies the optimal clinical zone — providing reliable cohesive performance, excellent pseudoplasticity through standard cannulas, and full biocompatibility — without the excessive resistance of ultra-high-concentration formulations that can be challenging to aspirate completely.

Biocompatibility and Degradation

HA is inherently biocompatible because the body already produces it. Residual HA after surgical removal is degraded by native hyaluronidase enzymes — it does not persist as a foreign body, does not elicit macrophage activation at clinical concentrations, and does not cause chronic anterior chamber inflammation. This safety profile has been confirmed in over 50 years of clinical data.

HPMC — The Dispersive Standard

Hydroxypropyl methylcellulose (HPMC) is a semi-synthetic cellulose ether produced by controlled alkylation of natural cellulose. It has been used in ophthalmic surgery since the early 1980s and remains clinically essential — particularly in high-volume surgical programmes in emerging markets — for its cost-effectiveness, dispersive protection, and room-temperature stability in many formulations.

Clinical Profile

• Standard concentration: 2.0%; high-viscosity formulations (PURE-VISC) at 2.5%
• Viscosity: Substantially lower than HA at zero shear; stable under moderate shear rates
• Dispersive behaviour: Fragments upon aspiration, reforming a protective endothelial coat even during irrigation
• Temperature stability: Many HPMC formulations do not require cold-chain refrigeration
• Cost profile: Significantly more affordable than HA — making it the primary OVD in large-scale cataract programmes across Asia, Africa, and Latin America

OVD Selection — A Clinical Decision Framework

OVD selection in contemporary cataract surgery is no longer a single, fixed choice — it is a case-by-case clinical decision that should incorporate patient risk factors, surgical complexity, nuclear density, and the specific IOL platform being implanted.

OVD-Related Complications — Causes, Recognition, and Prevention

Transient Ocular Hypertension

The most common OVD complication. Incidence: 4–40% depending on OVD type, removal thoroughness, and patient risk factors. Mechanism: residual OVD physically obstructs trabecular meshwork outflow, elevating IOP 4–24 hours post-operatively. Prevention: complete I/A with 180° sweep behind the IOL; prophylactic brimonidine in high-risk cases. Monitoring: IOP check at 4–6 hours post-operatively for glaucoma patients and pseudoexfoliation cases.

Corneal Oedema from Inadequate Protection

Paradoxically, insufficient OVD — particularly during prolonged phaco cases — is a cause of endothelial cell loss and resulting corneal oedema. The solution: active dispersive OVD refill between quadrant removal in any case exceeding 60 seconds of effective phaco time, or whenever anterior chamber turbulence is noted. Postoperative corneal clarity considerations are directly related to why vision quality varies after cataract surgery.

Retained OVD in the Posterior Segment

In cases complicated by posterior capsule rupture, OVD may prolapse into the vitreous. HA in the vitreous cavity causes significant IOP elevation and, in prolonged cases, potential retinal toxicity. In any case with vitreous loss, thorough anterior vitrectomy must precede OVD removal. For vitreoretinal surgical context, Agaaz's RETSIL silicone oils are part of the retinal tamponade continuum relevant when vitreoretinal complications arise from anterior segment cases.

OVDs and IOL Selection — An Interconnected Decision

OVD choice cannot be decoupled from IOL choice. Each lens material and design interacts differently with the viscoelastic environment — affecting deployment speed, centration accuracy, and the precision required from the OVD.

Hydrophilic foldable lenses like OP-FOLD AS unfold rapidly at body temperature. A cohesive OVD must resist this deployment force, keeping the capsular bag stable while the lens reaches its full optic diameter.

Hydrophobic foldable lenses like OP-VIEW AS deploy more slowly — giving the surgeon additional positioning time but requiring the OVD to remain stable in the bag for a longer interval before I/A.

Premium EDOF and trifocal lenses like X-VIZ demand the highest capsular precision of all. A 0.3mm centration error with a diffractive EDOF optic can produce clinically significant dysphotopsia. At this level, only a premium cohesive OVD delivering consistent, reliable capsular expansion is appropriate. For a full comparison of premium lens platforms, see our authoritative guide on monofocal vs multifocal vs trifocal vs EDOF IOLs.

The Future of Ophthalmic Viscoelastics

The science of OVDs is far from static. Several active research and development frontiers are currently reshaping what viscoelastics can and will do:

• Hybrid OVD formulations: Single-syringe products combining sodium hyaluronate with chondroitin sulphate or HPMC to deliver cohesive and dispersive properties simultaneously — without the soft-shell technique's two-step injection. Agaaz's upcoming PURE-HYAL CN (Na Hyaluronate + Chondroitin) addresses this need directly.
• Drug-eluting OVDs: Formulations incorporating intracameral antibiotics (see MOXGUARD), anti-inflammatories, or mydriatics for site-specific pharmacological delivery at the time of surgery.
• Sustained-release viscoelastics: Slowly biodegrading OVDs designed to maintain IOP stability and endothelial protection into the first 48–72 hours post-operatively — reducing the dependency on post-operative topical regimens.
• Smart responsive polymers: pH-responsive and thermo-responsive materials that adjust their physical properties in real time based on intraoperative conditions — the next major leap in surgical biomaterial design.

The global ophthalmic viscoelastic market is projected to reach USD 750 million by 2030, driven by rising cataract surgery volumes in Asia, Africa, and Latin America — the regions where Agaaz Ophthalmics has its deepest distribution presence. For broader context on where cataract surgery is headed, our article on the future of cataract surgery and AI-enabled IOLs provides the strategic landscape.

Clinical Takeaways — What Every Surgeon Must Know

• OVDs are non-negotiable in phacoemulsification — every step from capsulorhexis to IOL insertion depends on appropriate viscoelastic management.
• Cohesive = space; dispersive = protection. PURE-HYAL for chamber maintenance. OP-VISC for endothelial coating under phaco energy.
• The soft-shell technique (Arshinoff, 1999) combines both types — dispersive first to coat the endothelium, cohesive second to fill the chamber — and is the evidence-based standard for all high-risk cases.
• OVD removal is as critical as OVD injection. Residual OVD behind the IOL is the primary cause of post-operative IOP spikes. Meticulous bimanual I/A with 180° rotation is mandatory in every case.
• OVD choice is IOL-dependent. Premium EDOF and trifocal lenses require premium cohesive OVDs. The quality of capsular inflation directly determines the precision of IOL centration.
• Emerging technologies — hybrid OVDs, drug-eluting formulations, sustained-release viscoelastics — will redefine the OVD's role in the surgical ecosystem over the next decade.